EGFR+ NSCLC Combination Therapies Improve Outcomes but Increase Side Effects: Patient-Specific Factors Essential for Treatment Decisions

Combining therapies for EGFR-positive non-small cell lung cancer (NSCLC) simultaneously increases both the benefits and risks for patients, a panelist reported. Treatment plans should therefore be tailored to individual patients, taking into account a range of factors. The panelist highlighted that while combination therapies can improve progression-free survival, response rates, and duration of response, they also increase the likelihood of adverse effects. Consequently, treatment selection necessitates a careful evaluation of patient-specific factors. These factors include the presence of central nervous system (CNS) metastases, the patient’s performance status, their preferences regarding treatment aggressiveness, and real-world limitations. The panelist noted that patients in clinical practice often differ from those enrolled in clinical trials, presenting with conditions such as organ dysfunction, concomitant medications, and a history of previous treatments.

Newsflash | Powered by GeneOnline AI
Date: April 25, 2025

Related posts:

What the PlayStation Network Outage Can Teach the Biotech Industry How the Brain Rewires Itself for Language Recovery After a Stroke Study Reveals Mindfulness Reduces Anxiety and Improves Sleep in COPD Patients New Study Reveals Pursuit of Happiness May Lead to Increased Unhappiness

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後